# Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

> **NCT03814187** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 3275 (actual)

## Conditions studied

- ASCVD
- Elevated Cholesterol
- Heterozygous Familial Hypercholesterolemia
- Homozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** Inclisiran Sodium

## Key facts

- **NCT ID:** NCT03814187
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-16
- **Primary completion:** 2023-02-13
- **Final completion:** 2023-02-13
- **Target enrollment:** 3275 (ACTUAL)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03814187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03814187, "Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03814187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*